Lb Pharmaceuticals (LBRX) Retained Earnings (2024 - 2026)

Lb Pharmaceuticals has reported Retained Earnings for 3 years, with the latest figure at $208000.0 in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings changed N/A year-over-year to $208000.0; the trailing twelve-month figure through Mar 2026 stood at $208000.0 (changed N/A YoY), and the FY2025 full-year result was -$129.5 million, down 24.16% from the prior year.
• Retained Earnings for Q1 2026 stood at $208000.0, up from -$129.5 million in the prior quarter.
• The five-year high for Retained Earnings was $208000.0 in Q1 2026, with the low at -$129.5 million in Q4 2025.
• Average Retained Earnings over 3 years is -$58.4 million, with a median of -$52.2 million recorded in 2024.
• Peak annual rise in Retained Earnings reached 24.16% in 2025, while the deepest fall reached 24.16% in 2025.
• Tracing LBRX's Retained Earnings over 3 years: stood at -$104.3 million in 2024, then slipped by 24.16% to -$129.5 million in 2025, then soared by 100.16% to $208000.0 in 2026.
• The last three Retained Earnings figures came in at $208000.0 (Q1 2026), -$129.5 million (Q4 2025), and -$53000.0 (Q3 2025), per Business Quant data.

Peer Comparison